文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

值得局部治疗吗——寡转移性前列腺癌现代放疗概念分析

Worth a local treatment? - Analysis of modern radiotherapy concepts for oligometastatic prostate cancer.
PubMed 文献 · Radiat Oncol · 2018-09-21

本研究回顾性分析了2012年4月至2017年4月在本院接受放疗的27例寡转移性前列腺癌患者(19例淋巴结转移、8例单发骨转移),评估放疗作为复发前列腺癌治疗选择的可行性与局部控制及毒性。结果显示淋巴结转移组1年无转移生存率75.4%、2年58.7%,骨转移组1年100%、2年83.3%,淋巴结组局部控制率100%,毒性以轻中度为主,仅1例III°毒性。

要点

  • 淋巴结转移组放疗后中位PSA由2.6 ng/ml降至0.3 ng/ml(p=0.003),骨转移组由4.9 ng/ml降至0.14 ng/ml(p=0.004)。
  • 淋巴结转移组1年无转移生存率75.4%、2年58.7%;骨转移组1年100%、2年83.3%。
  • 淋巴结转移组局部控制率100%,毒性以轻中度为主,仅1例III°毒性。

核心结论

  • 作者认为放疗是复发性前列腺癌的一种可行治疗选择,局部控制优异且毒性较低。

研究设计与样本

  • 2012年4月至2017年4月在本院接受放疗的27例寡转移性前列腺癌患者,其中淋巴结转移19例、单发骨转移8例。

主要发现

  • 淋巴结转移组无转移生存期为24.8个月(22.0-36.0个月),骨转移组为25.4个月(23.9-28.1个月)。
  • 淋巴结转移组1年无转移生存率75.4%、2年58.7%;骨转移组1年100%、2年83.3%。
  • 淋巴结转移组放疗前中位PSA为2.6 ng/ml,放疗后中位PSA为0.3 ng/ml(p=0.003),中位生化无失败生存期为12.2个月。
  • 骨转移组治疗前中位PSA为4.9 ng/ml,治疗后降至0.14 ng/ml(p=0.004)。
  • 初始局限于前列腺的患者生化无失败生存期更优(p<0.001),无转移生存期也更优(p=0.013);毒性以轻中度为主,仅1例III°毒性;淋巴结转移组无死亡,总生存率100%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PCA) is the most-prevalent non-skin cancer in men worldwide. Nevertheless, the treatment of oligometastatic, especially lymph-node (ln) recurrent, PCA remains elusive. The aim of our study was to provide insights in radiotherapy (RT)-treatment of recurrent PCA exhibiting ln- or osseous (oss)-oligometastases. METHODS: Between April 2012 and April 2017, 27 oligometastatic PCA patients (19 ln and 8 single oss) were treated with RT at our institution. RESULTS: The metastasis-free survival (MFS) was 24.8 m (22.0-36.0 m) and 25.4 m (23.9-28.1 m) for the ln- and oss-subgroup resulting in 1-year MFS of 75.4 and 100% and 2-year MFS of 58.7 and 83.3% for ln- and oss-metastatic patients, respectively. Of notice, none of the recurrences for ln-patients was in the RT-field, constituting a local control of 100%. Within the ln-group, pre-RT median-PSA was 2.6 ng/ml, median post-RT PSA was 0.3 ng/ml, which was significant (p = 0.003). Median biochemical-free survival (bfS) was 12.2 m. PCA that was initially confined to the prostate had a better bfS (p < 0.001) and MFS (p = 0.013). The oss-group had a median PSA of 4.9 ng/ml pre-treatment which dropped to a median value of 0.14 ng/ml (p = 0.004). Toxicities were moderate, with only 1 case of III° toxicity. There were no deaths in the ln-group, thus overall survial was 100% here. CONCLUSION: Our study points out the feasibility of RT as a treatment option in recurrent PCA and demonstrates an excellent local control with a low-toxicity profile.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Oertel M, Scobioala S, Kroeger K, et al. Worth a local treatment? - Analysis of modern radiotherapy concepts for oligometastatic prostate cancer. Radiat Oncol. 2018. PMID: 30241556. doi:10.1186/s13014-018-1118-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。